These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 7600120)

  • 21. Standard heparin versus low-molecular-weight heparin. A medium-term comparison in hemodialysis.
    Stefoni S; Cianciolo G; Donati G; Colì L; La Manna G; Raimondi C; Dalmastri V; Orlandi V; D'Addio F
    Nephron; 2002; 92(3):589-600. PubMed ID: 12372942
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Future alternatives to heparin: low-molecular-weight heparin and hirudin.
    Donayre CE; Ouriel K; Rhee RY; Shortell CK
    J Vasc Surg; 1992 Apr; 15(4):675-82. PubMed ID: 1313932
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of antithrombotic and hemorrhagic effects of edoxaban, a novel factor Xa inhibitor, with unfractionated heparin, dalteparin, lepirudin and warfarin in rats.
    Morishima Y; Honda Y; Kamisato C; Shibano T
    Thromb Res; 2013 Aug; 132(2):234-9. PubMed ID: 23768448
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of the effects of different low molecular weight heparins on the hemostatic system activation in vivo in man.
    Wolzt M; Eder M; Weltermann A; Entlicher J; Eichler HG; Kyrle PA
    Thromb Haemost; 1997 Aug; 78(2):876-9. PubMed ID: 9268188
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative studies on the inhibitory spectrum of recombinant hirudin, DuP 714 and heparin on thrombin and factor Xa generation in biochemically defined systems.
    Kaiser B; Callas D; Hoppensteadt D; Mallinowska K; Fareed J
    Thromb Res; 1994 Mar; 73(5):327-35. PubMed ID: 8016817
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recombinant hirudin as a periprocedural antithrombotic in coronary angioplasty for unstable angina pectoris.
    Hafner G; Rupprecht HJ; Luz M; Terres W; Schindel F; Friesen HJ; Heinrichs H; Jessel A; Meyer J; Prellwitz W
    Eur Heart J; 1996 Aug; 17(8):1207-15. PubMed ID: 8869862
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A low-molecular-weight heparin (Kabi 2165, 'Fragmin') in repeated use for haemodialysis: prevention of clotting and prolongation of the venous compression time in comparison with commercial unfractionated heparin.
    Anastassiades E; Ireland H; Flynn A; Lane DA; Curtis JR
    Nephrol Dial Transplant; 1990; 5(2):135-40. PubMed ID: 2162506
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of hirudin versus heparin on hemocompatibility of blood contacting biomaterials: an in vitro study.
    Kopp R; Bernsberg R; Kashefi A; Mottaghy K; Rossaint R; Kuhlen R
    Int J Artif Organs; 2005 Dec; 28(12):1272-7. PubMed ID: 16404704
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rebound thrombin generation after heparin therapy in unstable angina. A randomized comparison between unfractionated and low-molecular-weight heparin.
    Bijsterveld NR; Moons AH; Meijers JC; Tijssen JG; Büller HR; Levi M; Peters RJ
    J Am Coll Cardiol; 2002 Mar; 39(5):811-7. PubMed ID: 11869846
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of unfractionated heparin, low molecular weight heparin and r-hirudin on leukocyte adhesion in ischemia/reperfusion.
    Habazettl H; Lindert J; Baeter S; Neumann K; Kuppe H; Kuebler WM; Pries AR; Koster A
    Blood Coagul Fibrinolysis; 2004 Jul; 15(5):375-81. PubMed ID: 15205585
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chrono-pharmacological study of once daily curative dose of a low molecular weight heparin (200 IU antiXa/kg of Dalteparin) in ten healthy volunteers.
    Mismetti P; Reynaud J; Tardy-Ponce B; Laporte-Simitsidis S; Scully M; Goodwyn C; Queneau P; Decousus H
    Thromb Haemost; 1995 Aug; 74(2):660-6. PubMed ID: 8585003
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activation of coagulation and platelets by candidate membranes of implantable devices in a whole blood model without soluble anticoagulant.
    Sokolov A; Hellerud BC; Tønnessen TI; Johannessen EA; Mollnes TE
    J Biomed Mater Res A; 2013 Feb; 101(2):575-81. PubMed ID: 22949225
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Markers of hemostatic system activation during thromboprophylaxis with recombinant hirudin in total hip replacement.
    Cofrancesco E; Cortellaro M; Leonardi P; Corradi A; Ravasi F; Bertocchi F
    Thromb Haemost; 1996 Mar; 75(3):407-11. PubMed ID: 8701398
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the antithrombotic effect of the new recombinant hirudin HBW 023 and heparin in small arteries and veins.
    Zhang B; Wieslander JB
    Microsurgery; 1996; 17(2):89-96. PubMed ID: 8914063
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of edoxaban on markers of coagulation in venous and shed blood compared with fondaparinux.
    Wolzt M; Samama MM; Kapiotis S; Ogata K; Mendell J; Kunitada S
    Thromb Haemost; 2011 Jun; 105(6):1080-90. PubMed ID: 21544313
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prothrombin fragment 1 + 2, thrombin-antithrombin III-complexes and fibrinopeptide A in spontaneously clotting whole blood in vitro. Effects of heparin addition and antithrombin III deficiency.
    Herren T; Straub PW; Haeberli A
    Thromb Haemost; 1994 Jan; 71(1):49-53. PubMed ID: 8165646
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of hirudin vs heparin on haemostatic activity in patients with acute coronary syndromes; the GUSTO-IIb haemostasis substudy.
    Kottke-Marchant K; Bahit MC; Granger CB; Zoldhelyi P; Ardissino D; Brooks L; Griffin JH; Potthoff RF; Van de Werf F; Califf RM; Topol EJ
    Eur Heart J; 2002 Aug; 23(15):1202-12. PubMed ID: 12127922
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Coagulation activation markers in the prediction of venous thrombosis after elective hip surgery.
    Cofrancesco E; Cortellaro M; Corradi A; Ravasi F; Bertocchi F
    Thromb Haemost; 1997 Feb; 77(2):267-9. PubMed ID: 9157579
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low molecular weight heparin inhibits plasma thrombin generation via direct targeting of factor IXa: contribution of the serpin-independent mechanism.
    Buyue Y; Misenheimer TM; Sheehan JP
    J Thromb Haemost; 2012 Oct; 10(10):2086-98. PubMed ID: 22905983
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics and pharmacodynamics of a low molecular weight heparin (enoxaparin) after subcutaneous injection, comparison with unfractionated heparin--a three way cross over study in human volunteers.
    Bendetowicz AV; Béguin S; Caplain H; Hemker HC
    Thromb Haemost; 1994 Mar; 71(3):305-13. PubMed ID: 8029794
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.